AGUNCO Obstetrics and Gynecology Centre
Quick facts
Marketed products
- Drospirenone Ethinyl estradiol
COCs reduce pregnancy risk mainly by preventing ovulation. - Drospirenone Ethinyl estradiol Myo-inositol · Gynecology / Reproductive Health
This combination oral contraceptive suppresses ovulation through progestin and estrogen activity while myo-inositol may improve insulin sensitivity and metabolic parameters. - Folic acid, vit B12 · Obstetrics and Gynecology / Nutritional supplementation
Folic acid and vitamin B12 work together to support DNA synthesis, cell division, and red blood cell formation, with particular importance during pregnancy for fetal development. - Recombinant FSH (rFSH) · Reproductive Medicine / Fertility
Recombinant FSH (follicle-stimulating hormone) stimulates the growth and maturation of ovarian follicles in women undergoing fertility treatment.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- AGUNCO Obstetrics and Gynecology Centre portfolio CI brief
- AGUNCO Obstetrics and Gynecology Centre pipeline updates RSS
Frequently asked questions about AGUNCO Obstetrics and Gynecology Centre
What are AGUNCO Obstetrics and Gynecology Centre's marketed drugs?
Top marketed products include Drospirenone Ethinyl estradiol, Drospirenone Ethinyl estradiol Myo-inositol, Folic acid, vit B12, Recombinant FSH (rFSH).
Related
- Drospirenone Ethinyl estradiol
- Drospirenone Ethinyl estradiol Myo-inositol · Gynecology / Reproductive Health
- Folic acid, vit B12 · Obstetrics and Gynecology / Nutritional supplementation
- Recombinant FSH (rFSH) · Reproductive Medicine / Fertility
- Sector hub: All tracked pharma companies